Related Experiment Videos
Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to
W H Oertel1, K Tatsch, J Schwarz
1Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-University, Federal Republic of Germany.
Annals of Neurology
|December 1, 1992
Summary
Wilson's disease patients show reduced dopamine D2 receptor binding in the brain, as seen with iodine-123-iodobenzamide (123I-IBZM) SPECT scans. This reduction correlates with the severity of neurological symptoms, indicating striatal neuronal damage.
Area of Science:
- Neuroscience
- Radiology
- Medical Imaging
Background:
- Wilson's disease is a genetic disorder causing copper accumulation, potentially leading to neurological damage.
- Dopamine D2 receptors are crucial for motor control and are implicated in various neurological conditions.
Purpose of the Study:
- To investigate dopamine D2 receptor densities in patients with Wilson's disease using 123I-iodobenzamide (IBZM) SPECT.
- To correlate receptor binding with the severity of neurological impairment in Wilson's disease.
Main Methods:
- Single-photon emission computed tomography (SPECT) with 123I-IBZM was performed on 17 Wilson's disease patients and 5 controls.
- Dopamine D2 receptor binding was quantified using the basal ganglia to frontal cortex ratio.
Main Results:
- A significant reduction in 123I-IBZM binding was observed in Wilson's disease patients compared to controls.
- Binding levels decreased with increasing neurological symptom severity, showing an almost linear correlation (r = -0.84, p < 0.01).
Conclusions:
- Reduced postsynaptic striatal dopamine D2 receptor density, detected by IBZM-SPECT, reflects striatal neuronal damage in Wilson's disease.
- 123I-IBZM SPECT may serve as a valuable tool for assessing neurological involvement in Wilson's disease.